5 155

Cited 0 times in

A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results.

Authors
 Hye Jin Choi  ;  Joo Hyuk Sohn  ;  Chang Geol Lee  ;  Hyo Sub Shim  ;  Ik-Jae Lee  ;  Woo Ick Yang  ;  Ji Eun Kwon  ;  Se Kyu Kim  ;  Moo-Suk Park  ;  Ju Hee Lee  ;  Joo Hang Kim 
Citation
 Lung Cancer, Vol.71(1) : 55-59, 2011 
Journal Title
 Lung Cancer 
ISSN
 0169-5002 
Issue Date
2011
Abstract
PURPOSE: This study was undertaken to determine safety and tolerability of nimotuzumab, a humanized anti-epidermal growth factor receptor monoclonal antibody, in combination with radiotherapy in stages IIB-IV non-small cell lung cancer (NSCLC) patients who are unsuitable for radical therapy or chemotherapy. METHODS: Nimotuzumab (100mg, 200mg and 400mg) was administered weekly from week 1 to week 8 with palliative radiotherapy (30-36 Gy, 3 Gy/day). If tumor control was achieved, nimotuzumab was continued every 2 weeks until unacceptable toxicity or disease progression. Serial skin biopsies were collected for pharmacodynamic assessment. RESULTS: Fifteen patients were enrolled in the study, with cohorts of five patients assigned in each dose level of nimotuzumab. Patients and disease characteristics included median age 73 years; Eastern Cooperative Oncology Group performance status (PS) 0-1/2 (n=3/12); female sex (n=2); adenocarcinoma (n=5); never-smoker status (n=2); and stages IIB/IIIB/IV (n=1/8/6). All patients were unable to tolerate radical therapy because of old age or multiple comorbidities. The most commonly reported adverse events were lymphopenia and asthenia (grades 1-2 in most patients). No skin rash or allergic toxicities appeared. Dose-limiting toxicity occurred with pneumonia with grade 4 neutropenia at the 200mg dose of nimotuzumab. Objective response rate and disease control rate inside the radiation field were 46.7% and 100.0%, respectively. CONCLUSIONS: Nimotuzumab in combination with radiotherapy is well-tolerated and feasible. Further clinical investigation of nimotuzumab in NSCLC patients is warranted.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/92720
Full Text
http://www.sciencedirect.com/science/article/pii/S0169500210001698
DOI
10.1016/j.lungcan.2010.04.010
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실)
Yonsei Authors
권지은(Kwon, Ji Eun)
김세규(Kim, Se Kyu)
김주항(Kim, Joo Hang)
박무석(Park, Moo Suk) ORCID logo https://orcid.org/0000-0003-0820-7615
손주혁(Sohn, Joo Hyuk)
심효섭(Shim, Hyo Sup) ORCID logo https://orcid.org/0000-0002-5718-3624
양우익(Yang, Woo Ick)
이익재(Lee, Ik Jae)
이주희(Lee, Ju Hee)
이창걸(Lee, Chang Geol)
최혜진(Choi, Hye Jin)
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse